ClearPoint Neuro (NASDAQ:CLPT) Issues Earnings Results

Key Points

• ClearPoint Neuro reported a quarterly earnings per share (EPS) of ($0.21), missing analysts' expectations by $0.01 and showing a negative return on equity of 78.09%.
• The company's stock fell by 0.6% to $10.54, with a market capitalization of $295.01 million and a PE ratio of -13.87.
• Several brokerages have revised their ratings for ClearPoint Neuro, with Wall Street Zen downgrading it to a "sell" and Stifel Nicolaus raising the target price to $9.00 while maintaining a "buy" rating.

ClearPoint Neuro (NASDAQ:CLPT - Get Free Report) issued its quarterly earnings data on Tuesday. The company reported ($0.21) EPS for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.01), Zacks reports. ClearPoint Neuro had a negative return on equity of 78.09% and a negative net margin of 64.51%. ClearPoint Neuro updated its FY 2025 guidance to EPS.

ClearPoint Neuro Stock Down 0.6%

ClearPoint Neuro stock traded down $0.06 during midday trading on Tuesday, hitting $10.54. 475,012 shares of the stock were exchanged, compared to its average volume of 312,132. The company has a fifty day simple moving average of $11.55 and a two-hundred day simple moving average of $13.18. ClearPoint Neuro has a 52 week low of $9.40 and a 52 week high of $19.22. The stock has a market capitalization of $295.01 million, a PE ratio of -13.87 and a beta of 0.85.

Insider Activity at ClearPoint Neuro

In related news, CEO Joseph Burnett sold 21,247 shares of ClearPoint Neuro stock in a transaction that occurred on Monday, June 9th. The shares were sold at an average price of $13.29, for a total transaction of $282,372.63. Following the transaction, the chief executive officer owned 243,522 shares of the company's stock, valued at $3,236,407.38. This trade represents a 8.02% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Timothy T. Richards sold 10,000 shares of ClearPoint Neuro stock in a transaction that occurred on Tuesday, June 10th. The stock was sold at an average price of $13.28, for a total transaction of $132,800.00. Following the transaction, the director directly owned 77,381 shares in the company, valued at $1,027,619.68. The trade was a 11.44% decrease in their position. The disclosure for this sale can be found here. 6.11% of the stock is owned by company insiders.

Institutional Trading of ClearPoint Neuro

Several hedge funds have recently bought and sold shares of the stock. Millennium Management LLC raised its holdings in ClearPoint Neuro by 156.3% during the 1st quarter. Millennium Management LLC now owns 741,193 shares of the company's stock worth $8,813,000 after buying an additional 452,043 shares during the period. Goldman Sachs Group Inc. raised its holdings in ClearPoint Neuro by 98.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 257,871 shares of the company's stock worth $3,066,000 after buying an additional 127,823 shares during the period. Rhumbline Advisers acquired a new stake in ClearPoint Neuro during the 2nd quarter worth approximately $450,000. JPMorgan Chase & Co. raised its holdings in ClearPoint Neuro by 35.4% during the 2nd quarter. JPMorgan Chase & Co. now owns 32,790 shares of the company's stock worth $392,000 after buying an additional 8,581 shares during the period. Finally, Legal & General Group Plc acquired a new stake in ClearPoint Neuro during the 2nd quarter worth approximately $35,000. 30.08% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages have recently issued reports on CLPT. Wall Street Zen lowered shares of ClearPoint Neuro from a "hold" rating to a "sell" rating in a research note on Saturday, July 12th. Stifel Nicolaus raised their target price on shares of ClearPoint Neuro from $8.00 to $9.00 and gave the company a "buy" rating in a research note on Friday, August 1st.

About ClearPoint Neuro

ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.